Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Minimal residual disease (MRD) analysis is a known predictive tool in mantle cell lymphoma (MCL). We describe MRD results from the Fondazione Italiana Linfomi phase 3 MCL0208 prospective clinical trial assessing lenalidomide (LEN) maintenance vs observation after autologous stem cell transplantation...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrero, Simone, Grimaldi, Daniele, Genuardi, Elisa, Drandi, Daniela, Zaccaria, Gian Maria, Alessandria, Beatrice, Ghislieri, Marco, Ferrante, Martina, Evangelista, Andrea, Mantoan, Barbara, De Luca, Gabriele, Stefani, Piero Maria, Benedetti, Fabio, Casaroli, Ivana, Zanni, Manuela, Castellino, Claudia, Pavone, Vincenzo, Petrini, Mario, Re, Francesca, Hohaus, Stefan, Musuraca, Gerardo, Cascavilla, Nicola, Ghiggi, Chiara, Liberati, Anna Marina, Cortelazzo, Sergio, Ladetto, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507010/
https://www.ncbi.nlm.nih.gov/pubmed/35737911
http://dx.doi.org/10.1182/blood.2021014270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507010/
https://www.ncbi.nlm.nih.gov/pubmed/35737911
http://dx.doi.org/10.1182/blood.2021014270

Ejemplares similares